Flagellin, as a TLR5 agonist, is an established mucosal adjuvant for enhancing mucosal IgA responses by i.n. immunization. Nasal epithelial cells (NECs) are the first sentinel cells to be exposed to antigen and adjuvant in i.n. immunization, and it is suggested that they play an important role in the mucosal adjuvant activity of flagellin. However, the molecular mechanism leading to modulation and the response by flagellin-activated NECs remain unknown. We aimed to identify the soluble mediator(s) from flagellin-activated NECs that modulate the functions of airway dendritic cells (DCs) and enhance subsequent IgA response. In vitro studies showed that compared with the TLR4 agonist LPS, flagellin directly triggered slight up-regulation of CD80 on airway DCs but was insufficient to affect CD86 expression and DCmediated IgA response. With the use of an in vitro system for culturing mouse primary NECs (mNECs), we demonstrated that flagellin-activated mNECs could functionally modulate airway DCs, which manifested as significant up-regulation of CD80/CD86 and enhancement of IgA production. The functional modulation of airway DCs was dependent on TLR5 activation of mNECs rather than direct TLR5 activation of airway DCs. With the use of cytokine array and antibody-blocking assays, we further identified that GM-CSF, a cytokine secreted from TLR5-activated mNECs, contributes to the activation of mNECs to airway DCs and subsequent IgA enhancement. In vivo blocking experiments confirmed that GM-CSF is an important factor in recombinant flagellin derived from Salmonella typhi (FliC)-induced airway DC activation and antigen-specific IgA enhancement. Our data directly demonstrate that nasal epithelial GM-CSF contributes to TLR5-mediated modulation of airway DCs and a subsequent IgA response.
Introduction
In the past decade, novel adjuvants that specifically target TLRs have been studied as part of the development of various vaccines [1] [2] [3] . Safe and efficient adjuvants for formulating mucosal vaccines to target early infection in mucosal sites are attracting increasing attention [4] . The TLR5 agonist flagellin has been proven as an effective mucosal adjuvant, in addition to its systemic adjuvant activity [5] , when administered via the i.n. route [6, 7] , which can prominently increase a protective IgA response [8, 9] . However, the mechanism by which flagellin drives a mucosal immune response when acting as an i.n. adjuvant remains undetermined.
DCs, as the most important professional APC, are crucial mediators between innate and adaptive immunity [10, 11] . The respiratory system is equipped with an elaborate network of DCs that can be found in the nose, nasal-associated lymphoid tissue, CLNs, lungs, and MdLNs. DCs have been proven to play a critical role in IgA responses [12, 13] in mucosal immunity. Suzuki et al. [14] found that LDCs were efficient at inducing IgA under T cell-dependent and T cell-independent conditions. GeurtsvanKessel et al. [15] showed that CD11c + LDCs are essential for the development of inducible bronchus-associated lymphoid tissue after influenza infection, and the depletion of CD11c + LDCs led to significant reductions in IgA-CSR in the lungs. Ruane et al. [16] further found that microbiota could regulate the ability of LDCs to mediate IgA-CSR. These findings support a hypothesis that DCs are a crucial cell type in the cellular mechanism of TLR5-mediated mucosal IgA induction. When delivered via a systemic route, flagellin performs its adjuvant activity through TLR5 and/or nucleotide-binding oligomerization domain-like receptor family, caspase activation and recruitment domain containing 4 [17] . Flagellin can activate DCs directly and efficiently, and TLR5 +/+ DCs are necessarily involved [18] . When delivered via an i.n. route, airway structural cells-probably respiratory epithelial cells-are responder cells to TLR5 stimulation in the regulation of the TLR5-mediated mucosal immune response [19] . Moreover, it has been proven that DCs are not the target cells of flagellin in i.n. immunization, as DCs are activated by indirect, rather than direct, TLR5 signaling [20] . However, direct evidence about the regulation of TLR5-mediated mucosal adjuvant activity by respiratory epithelial cells is lacking. Additionally, the above conclusions have caused confusion about the necessary role of DCs in TLR5-mediated mucosal adjuvant activity. TLRs are constitutively expressed in NECs, the upper section of AECs [21] . They confer to NECs the ability to respond and combat potential pathogens through recognition of PAMPs of microbes. Following PAMP recognition, NECs are capable of producing various cytokines, chemokines, and growth factors that induce the local recruitment and activation of DCs [22] . For example, CCL20 can recruit DCs, as well as T and B lymphocytes [23] , whereas TSLP can directly activate DCs by up-regulating costimulatory molecules, such as CD40, CD80, and CD86, to promote Th2 cell differentiation [24] . Furthermore, stimulated epithelial cells can produce BAFF/B lymphocyte stimulator and APRIL to promote the activation, differentiation, and survival of B cells [25] .
With the consideration of the above information, this study focused on the relevant roles of DCs and NECs in the adjuvant activity of flagellin and discovering the key epithelial factors involved in this process.
MATERIALS AND METHODS

Mice
Female C57BL/6 mice, aged 6-8 wk (18-20 g/mouse) were obtained from Hunan Laboratory Animal Research Center and housed in the Animal Center of WIV, CAS, under SPF conditions. C57BL/6 background Tlr5 2/2 mice, of
The Jackson Laboratory origin (Bar Harbor, ME, USA) were bred and housed in the Animal Center of WIV, CAS, under SPF conditions. Animal studies were performed according to Regulations for the Administration of Affairs Concerning Experimental Animals in China (1988) and the Guideline for Animal Care and Use (WIV, CAS). All animals were assigned randomly to groups before the experiment.
Flow cytometry
Single-cell suspensions of mouse nasal, lymph nodes, and lungs were prepared by digestion before staining, as described previously [14, 26, 27] . FcRs were blocked with anti-CD16/32 Fc block (2.4 G2; BD Biosciences, San Jose, CA, USA) for 25 min at 4°C. DCs from mouse tissue were stained with the following specific antibodies: FITC-labeled anti-B220 (RA3-6B2), PE-Cy7-labeled anti-CD11c (N418), allophycocyanin-labeled anti-I-A b (AF6-120.1), PE-Texas Red-labeled anti-CD80 (16-10A1), PE-labeled anti-CD86 (GL-1), and 7-AAD (all reagents from BioLegend, San Diego, CA, USA). In vitro-cultured DCs were stained with the following specific antibodies: FITC-labeled anti-B220 (RA3-6B2), PE-Cy7-labeled anti-CD11c (N418), PerCP-Cy5. . Amounts of 20 mg/ml anti-GM-CSF, 2 mg/ml anti-IL-6 and 4 mg/ml anti-TSLP were used [14, 28, 29] . Following stimulation, these DCs were harvested for detection or washed 3 times for further experiments.
Isolation of mNECs and preparation of conditioned medium from mNECs
Mouse nasal septa were harvested from female naive C57BL/6 mice (WT or Tlr5
), and the NECs were dissociated with 1.4 mg/ml Pronase (SigmaAldrich, St. Louis, MO, USA), plus 0.1 mg/ml DNase I (DN25; Sigma-Aldrich), as described previously [30] . mNEC cultures were grown on semipermeable support membranes (0.4 mm pore; Corning Costar Transwell clear 24-well plate inserts), coated with human type VI placental collagen (Rockland Antibodies & Assays, Limerick, PA, USA) as an air-liquid interface on tissueculture inserts for 14-16 d. After polarization, fresh medium, with or without 10 29 M FliC, was placed on the apical side of the polarized mNECs. After 24 h, conditioned medium from both the apical and basolateral chambers was collected separately, and supernatants were separated into small aliquots after centrifugation and stored at 280°C in preparation for ELISA and functional assay.
Coculture of DCs and naive B cells
B cells were isolated from female C57BL/6 mouse splenic cells with anti-B220 mAb-coated magnetic beads, using a B Cell Isolation Kit (Miltenyi Biotec). Isolated B cells were incubated with FITC-labeled anti-IgD mAb (11-26c.2a;
(continued from previous page) mNEC = mouse primary nasal epithelial cell, NEC = nasal epithelial cell, NEC-M = conditioned medium from nasal epithelial cell, PAMP = pathogenassociated molecular pattern, PD = pixel density, RA = retinoic acid, SPF = specific pathogen free, Tlr5 
Cytokine assay
RayBio Mouse Cytokine Antibody Array C1 (RayBiotech Norcross, GA, USA) was used for the cytokine antibody assay, as described previously [31] . Signal intensities were quantified and analyzed with a chemiluminescence imaging system (FluorChem HD2; Alpha Innotech, Santa Clara, CA, USA). Spots were digitized into PDs for analysis, and the fold change for each protein was calculated as PD NEC-FliC/PD NEC-M. The concentrations of IL-6, GM-CSF, and TSLP were measured using an ELISA Max set (BioLegend). Experiments were operated according to the manufacturer's instructions.
In vivo neutralization
Mice received anti-GM-CSF mAb (MP1-22E9; BioXCell, West Lebanon, NH, USA) or control IgG2a (clone 2A3; BioXCell) i.p., injected twice with 0.35 mg/mouse at a time interval of 48 h. Four hours after the second antibody injection, mice were anesthetized, and 5 mg FliC in a 10 ml aliquot was administered i.n. to each mouse (5 ml/nostril). Another 4 h after i.n. administration, mice were euthanized and the entire nasal cavity sampled for detection of DCs. In another independent experiment, mice were euthanized at 18 h after i.n. administration, and CLN DCs were sampled for detection of 
Statistical analysis
Data are presented as means 6 SEM from 1 experiment that was repeated at least 3 times. All data analyses were performed with one-way ANOVA. When the P value was significant at the 5% level, further pairwise comparisons between the experimental group and control conditions were made using Bonferroni's test. Statistical analysis was carried out with InStat, version 5.0 (GraphPad Software, La Jolla, CA, USA). P ,0.05 was considered significant.
RESULTS
Nasal immunization with flagellin stimulates upper-airway mucosal DCs through TLR5 signaling and enhances IgA production
To dissect the activation mechanism of airway mucosal DCs in nasal immunization with flagellin, we first tested the stimulation of airway mucosal DCs in mice at different time points after i.n. administration of 5 mg FliC in 10 ml vol. B220
2 CD11c + I-A b+ cells
were gated and analyzed as airway DCs in the nose, CLN, lung, and MdLN (Supplemental Fig. 1 ). We found that following i.n. administration of FliC, nasal DCs were stimulated swiftly with increased expression of CD80 and CD86 at 4 h and then declined gradually, returning to baseline levels at 12 h ( Fig. 1A and B) . Meanwhile, DCs in CLNs showed a gradual activation, by increased expression of CD80 and CD86 from 0 to 18 h postadministration. However, no significant CD80 and CD86 Altogether, these data confirmed that i.n. administration of flagellin in 10 ml vol can stimulate DCs in the nose and CLN efficiently through the TLR5 signaling pathway. Previous studies showed that i.n. administration of flagellin in 30 ml vol activated lung MdLN DCs efficiently [20] . Indeed, as shown in Supplemental Fig. 2 , the activation mode of DCs in the upper-or lower-airway respiratory system was associated with i.n.
volume. An amount of 5 mg FliC/10 ml did not activate lung and MdLN DCs, whereas 5/30 ml did. We considered that this distinction was derived from different inhaled volumes. With 10 ml i.n. vol, flagellin remained only in the local nasal passage and only triggered TLR5 activation in the upper respiratory tract. With 30 ml i.n. vol, the liquid flowed into the lung, resulting in activation in the upper and lower respiratory tracts.
To test whether the flagellin-activated airway DCs could exert this driving force on B cells and enhance IgA induction, we designed an ex vivo experiment by sorting CLN DCs 24 h after i.n. immunization with FliC or PBS. The sorted DCs were cocultured with syngenic IgD + naive B cells for 7 d, and total IgA production was evaluated using ELISA [14] . Both groups of CLN DCs were able to induce IgA from naive B cells compared with naive B cells cultured alone (Fig. 1D) . Moreover, DCs from WT mice immunized with FliC had a significantly higher ability to induce IgA than DCs from WT mice immunized with PBS ( Fig.  1D , black bars). In contrast, no significant difference in IgA production induced by DCs from immunized Tlr5 2/2 mice, with and without FliC (white bars), was observed. Therefore, nasal immunization with flagellin not only stimulates airway mucosal DCs through TLR5 signaling but also enhances IgA production.
Flagellin directly triggers slight up-regulation of CD80 in airway DCs but does not affect CD86 expression or DC-mediated IgA response
We have shown that i.n. immunization of mice with flagellin stimulates airway mucosal DCs in a TLR5-dependent manner and enhances IgA production. There are two possible mechanisms by which the flagellin molecule interacts with nasal mucosal DCs: directly or indirectly. Under i.n. immunization with flagellin, the NECs are the first target cells for flagellin uptake and cell interaction. After passing through the nasal epithelial barrier and reaching the lamina propia layer, the flagellin molecule may potentially interact with DCs residing in airway mucosa. Once the nasal mucosal DCs are stimulated, they usually migrate to the CLN and mediate further T and B cell responses [32, 33] . To test the interaction mechanism of flagellin with NECs and mucosal DCs, we first detected the uptake of flagellin by nasal mucosa after nasal administration of flagellin. With the use of immunohistochemical staining on nose paraffin sections, quick and efficient uptake of flagellin molecules by nasal mucosa could be observed at 30 min after nasal administration (Supplemental Fig. 3 ). The results suggest that nasal mucosal DCs may have opportunity to capture and interact with flagellin after nasal immunization. We then examined the direct effect of treatment with FliC on upper-airway DCs in vitro. Nasal DCs are the first choice for use in investigation of DCs of upper-airway origin. However, the attainment of sufficient numbers of nasal DCs for functional assays was difficult and infeasible. CLN DCs were used as an alternative, including nasal DCs that migrated to CLN when matured or activated [32] . In brief, mouse CLN CD11c + DCs were extracted from WT or Tlr5 2/2 mice, stimulated with FliC, and assayed for expression of CD80/CD86. DCs treated with medium only or TLR4 agonist LPS were used as blank and positive controls, respectively. FliC was found to induce slight upregulation of CD80 on WT DCs ( Fig. 2A , left, and C, black bars) but had no effect on CD86 expression for either WT DCs (Fig.  2B , left, and D, black bars) or CD80 and CD86 on Tlr5 2/2 DCs ( Fig. 2A and B, right, and C and D, white bars), compared with blank control, whereas LPS activated both WT and Tlr5 2/2 DCs efficiently with evident enhancement of CD80/CD86 expression ( Fig. 2A-D) . Next, with the use of an in vitro DC naive B cell coculturing system [14] , we tested whether flagellin-stimulated DCs could enhance IgA induction. After stimulation with medium or FliC or LPS, CLN DCs were washed extensively and cocultured with naive B cells for 7 d. The supernatant and cells of the coculture were collected and assayed for IgA production and IgA-secreting cells. Regardless of the source of the DCs, no significant difference was observed in either IgA production (Fig. 2E) or FliC in PBS (5 mg) or PBS alone in a 10 ml aliquot. CLN cells were pooled, and DCs were sorted 24 h postimmunization. IgA induction was evaluated using ELISA, 7 d after coculturing the sorted DC populations with IgD + naive B cells (2:1 ratio) in triplicates in the presence of 1 mg/ml LPS, 1 mg/ml anti-CD40, and 0.15 mg/ml anti-IgM. MFI, Mean fluorescence intensity. *P , 0.05; **P , 0.01; ***P , 0.001; n.s., no statistically significant difference between groups. The results are representative of 3 independent experiments.
IgA-secreting cells (Fig. 2F) between the FliC-stimulated (FliC) and nonstimulated (medium) DCs, whereas significantly increased IgA production was induced by LPS-stimulated DCs compared with nonstimulated (medium) DCs (Fig. 2E) . These results showed that flagellin can directly stimulate up-regulation of CD80 on airway DCs but does not affect CD86 expression and was insufficient to affect the DC-mediated IgA response in our experiment system.
Flagellin stimulates airway DCs and initially promotes DC-mediated IgA enhancement through TLR5-stimulated mNECs
As direct stimulation of airway DCs with flagellin was insufficient to activate DCs or enhance the DC-mediated IgA response, we hypothesized that DCs residing in airway mucosa might be activated efficiently and functionally by upstream factors derived from flagellin-activated NECs indirectly. Therefore, we further examined the possible indirect effect of flagellin treatment through NECs on airway DCs. As previously described, an in vitro primary mNEC culture system was adopted, with slight modification, to examine the role of NECs in flagellin-mediated adjuvant activity. In brief, mNECs were separated and cultured in a 2-chamber Transwell for cell differentiation and to form an intact polarized cell monolayer. The integrity and polarization of the cell monolayer were monitored by transepithelial electrical resistance (Supplemental Fig. 4A ) and zonula occludens 1 expression (Supplemental Fig. 4B ). Immune staining showed that TLR5 was expressed in the cultured mNECs, although the more-notable signal was located on the apical side (Supplemental Fig. 4C ). This is identical to in vivo expression of TLR5 in both single-layer and pseudostratified ciliated columnar epithelium of the mouse nasal cavity (Supplemental Fig. 4D) .
To test the activation of mNECs stimulated by flagellin and the subsequent indirect modulation effect on mucosal DC function, the above-described, well-differentiated, and polarized mNECs were apically treated with FliC or medium alone as control. The apical and basolateral supernatants were then collected separately as conditioned media for modulation effect assays of DC activation and function. The collected conditioned medium from the mNECs was applied to treat CLN DCs. After treatment, the stimulated DCs were collected for activation and function assays (the experimental procedures are illustrated in Fig. 3A) .
When WT CLN DCs were stimulated with WT NEC-FliC and assayed for expression of CD80/CD86, conditioned medium collected from either apical or basolateral chambers showed similar results. Therefore, a mixture of the apical and basolateral conditioned medium was used in the repeat experiments.
WT NEC-FliC significantly up-regulated the expression of CD80 and CD86 on WT DCs compared with the WT NEC-M. However, although the Tlr5 2/2 NEC-FliC up-regulated the expression of CD80 on WT DCs (Fig. 3B, black bars) , it had no effect on CD86 (Fig. 3C, black bars) . This CD80 up-regulation in the presence of 1 mg/ml LPS, 1 mg/ml anti-CD40, and 0.15 mg/ml anti-IgM. The coculture supernatants were collected 7 d later for total IgA detection using ELISA (E), and cells were harvested for IgA + cell analysis (F). FACS analysis of IgA + cells was gated on 7-AAD 2 viable cells. *P , 0.05; ***P , 0.001; n.s., no statistically significant difference between groups.
The results are representative of 3 independent experiments.
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www.jleukbio.org could have been caused by FliC residue in the conditioned medium. The result demonstrated that the conditioned medium from flagellin-activated mNECs modulates airway DCs dependent on TLR5 expression in mNECs. Next, the modulated DCs were tested for their function in facilitating antibody production of B cells by measuring both IgA production and percentage of IgA-secreting cells. Results showed that DCs treated with WT NEC-FliC helped B cells to produce significantly higher amounts of IgA (Fig. 3D, black  bars) ; the percentage of IgA-secreting cells in the B cell population (Fig. 3E , black bars) was higher than in the DCs treated with WT NEC-M. However, DCs treated with Tlr5 2/2 NEC-FliC had no evident effect on either IgA production (Fig.  3D, black bars) or percentage of IgA-secreting cells (Fig. 3E,  black bars) . These results demonstrated that flagellin modulates airway DCs and promotes DC-mediated IgA production efficiently, through activation of mNECs in a TLR5-dependent manner.
In parallel, when Tlr5 2/2 DCs were tested as above, similar results could be observed in the WT DCs, both in DC activation ( Fig. 3B and C, white bars) and function, facilitating naive B cells to produce IgA (white bars of Fig. 3D and E). This suggests that TLR5 signaling in epithelial cells, but not DCs, is necessary to trigger DC activation. These results further demonstrated that flagellin stimulates airway DCs and promotes DC-mediated IgA enhancement, initially through TLR5-activated mNECs.
TLR5-activated mNECs secrete specific cytokines
Next, we investigated related factor(s) in the conditioned medium of TLR5-activated mNECs that drive DC activation and subsequent IgA enhancement. As TLR5 is constitutively expressed on mNECs and is notably located on the apical side (Supplemental Fig. 4B and C) , the stimulation of mNECs with FliC may lead to expression and release of various active proteins, especially cytokines and chemokines. Therefore, we analyzed the cytokine profile produced by FliC-activated mNECs using a cytokine chip assay (Fig. 4A) . WT or Tlr5 2/2 mNECs were treated with FliC or medium alone as a control; both apical and basolateral supernatant was collected and mixed and then assayed for cytokine production. The cultured mNECs (WT NEC-M) constitutively expressed and released several cytokines, and FliC-activated mNECs (WT NEC-FliC) showed evident increases in 6 proteins in the tested array. These included 4 cytokines-GM-CSF, G-CSF, IL-6, and IL-12 p40/70-and 2 chemokines-KC and MCP-1 (Fig. 4B, upper) . In contrast, FliC-activated mNECs from Tlr5 2/2 mice (Tlr5 2/2 NEC-FliC)
showed no difference in cytokine expression to that of nonactivated mNECs (Tlr5 2/2 NEC-M; Fig. 4B , lower).
Compared with the nonactivated WT mNECs (WT NEC-M), FliC-activated WT mNECs (WT NEC-FliC) secreted ;95-fold more GM-CSF, 16.6-fold more G-CSF, 14.4-fold more IL-12 p40/70, 4.82-fold more IL-6, 1.73-fold more MCP-1, and 4.8-fold more KC into conditioned medium (Fig. 4C, black bars) . However, FliC-activated Tlr5 2/2 mNECs (Tlr5 2/2 NEC-FliC) showed no change compared with nonactivated Tlr5 2/2 mNECs (Tlr5 2/2 NEC-M) in all 6 cytokines/chemokines (Fig. 4C, white bars). This suggested that the changes to the 6 cytokines/ chemokines in FliC-activated mNECs were TLR5 specific. Chemokines play roles in DC recruitment but not in activation, and so, KC and MCP-1 were excluded from further studies. Among the 4 cytokines, IL-12 is important in the enhancement of Th1 immunity, increasing T-lymphocyte cytotoxicity and inhibiting angiogenesis. IL-6 has been identified as a regulator for B cell Ig secretion [34] . Although GM-CSF and G-CSF are both established as granulocyte growth factors, the G-CSFR is predominantly expressed on neutrophils and drives their proliferation and maturation without any apparent effect on monocytes, eosinophils, or basophils [35] , whereas GM-CSF influences many myeloid cell types [36] .
Based on the magnitudes of change (Fig. 4C) and their known functions, as discussed above, we focused on GM-CSF and IL-6 in further studies. Although TSLP was not included in the cytokine chip array, it was chosen for further studies because of its known ability to direct activating DCs to promote Th2 cell differentiation [24] . APRIL and B cell-specific cytokine BAFF were excluded following reports that mRNA for APRIL and BAFF was not induced by TLR5 ligands tested in AECs in vitro [25] .
To confirm the antibody array results, we quantified the production of the 3 selected cytokines using an ELISA assay separately in the apical and basolateral supernatant. FliC significantly stimulated mNECs to produce GM-CSF and TSLP in both the apical and basolateral supernatant but only IL-6 in the apical supernatant compared with control medium or when performed with Tlr5 2/2 mNECs cells (Tlr5 2/2 NEC-FliC; Fig.   4D ). The data suggested that TLR5 activated mNEC expression and secretion of specific cytokines into the mucosal environment. Cytokines, such as GM-CSF, IL-6, and/or TSLP, may be soluble factors that convey signals from TLR5-stimulated NECs to airway DCs and promote DC-mediated IgA enhancement.
GM-CSF derived from TLR5-activated mNECs made a significant contribution to the conveyance of signals from mNECs to airway DCs
We then tested different cytokine candidates by measuring the inhibition effects using neutralizing antibodies acting against each cytokine. We found that GM-CSF is an essential factor involved in the whole activation pathway, from TLR5 stimulation of mNECs to functional activation of airway DCs and the subsequent IgA antibody production from B cells. Figure 5 shows the results of our representative experiments that tested with neutralizing antibodies against GM-CSF, IL-6, and/or TSLP. Firstly, we observed the inhibition effect on DC activation with neutralizing antibodies. As previously described, CLN DCs were isolated and treated with conditioned medium from FliC-activated mNECs (WT NEC-FliC) with the addition of cytokine-neutralizing antibodies or isotype antibodies as controls at concentrations recommended as indicated in Materials and Methods. The addition of an anti-GM-CSF antibody ( Fig. 5A and B, black bars) reduced CD80 and CD86 expression to a level similar to the background level induced by WT NEC-M (Fig. 5A and B, lower dashed lines), whereas the isotype control antibody (Fig. 5A and B, white bars) showed no effect. In contrast, treatment with anti-IL-6 mAb or anti-TSLP mAb exerted a marginal effect on expression of both CD80 and CD86. When antibodies were mixed together at the recommended doses, the additive effect of combination treatment was not significant (Fig. 5A and B) . These results suggest that GM-CSF, but not IL-6 and TSLP, may be an essential factor in the up-regulation of CD80 and CD86 expression of airway DCs in conditioned medium from TLR5-activated mNECs (WT NEC-FliC).
To investigate further whether GM-CSF is sufficient to activate airway DCs, various concentrations of rGM-CSF, from 10 pg/ml to 1 mg/ml, were added to 24 h cultures of CLN DCs directly (medium) or together with inactive supernatant from mNECs (Tlr5 2 /2 NEC-FliC). Active supernatant from flagellin-activated mNECs (WT NEC-FliC) was used as a positive control. Neither GM-CSF alone nor GM-CSF in addition in the inactive supernatant significantly up-regulated the expression of CD80 or CD86 on DCs. This indicated that rGM-CSF by itself was insufficient to activate airway DCs. These data suggested that some other factors produced from TLR5-activated mNECs are needed to synergize with GM-CSF for activation of airway DCs.
To confirm the above observation, we examined further whether the GM-CSF produced from flagellin-activated mNECs is essential for DC-mediated IgA production. After treatment in vitro using conditioned medium from FliCactivated mNECs, in addition to anti-GM-CSF, anti-IL-6, and anti-TSLP neutralizing antibody or isotype control antibody, the airway DCs were washed extensively and then cocultured with naive B cells for IgA production and IgA-secreting cells assay. Addition of anti-GM-CSF neutralizing antibody significantly impaired IgA production and decreased the percentage of IgA-secreting cells (Fig. 5C and D) , but addition of anti-IL-6 ( Fig. 5E and F) or anti-TSLP ( Fig. 5G and H) neutralizing antibody exerted no significant effect. This further demonstrated that GM-CSF, derived from TLR5-activated mNECs (WT NEC-FliC), made a significant contribution, not only to the modulation of nasal and CLN DCs but also to subsequent DC-mediated IgA production.
GM-CSF contributes to airway DC activation and antigen-specific IgA response in vivo
To confirm the contribution of GM-CSF derived from flagellinactivated NECs in the modulation of nasal DCs in vivo, we performed the GM-CSF-blocking experiments in mice. First, we tested the function of GM-CSF in flagellin-induced nasal and CLN DC activation. Anti-GM-CSF neutralizing mAb or isotype control antibody was injected i.p. twice into mice before i.n. administration of FliC, and the mice were tested for nasal DC activation at 4 h (Fig. 6A) or for the CLN DC activation at 18 h (Fig. 6B) postimmunization. As shown in Fig. 6A and B, blockade of GM-CSF in mice significantly impaired FliC-induced nasal DC activation (Fig. 6A ) and CLN DC activation (Fig. 6B) , indicated by significantly lowered CD80 and CD86 expression compared with the FliC group that was treated without anti-GM-CSF or isotype antibody.
To investigate further the contribution of GM-CSF in the flagellin-enhanced IgA response, we carried out a long-term immunization experiment with GM-CSF blocking in mice. In brief, mice were i.n. immunized with PBS, OVA, or OVA plus FliC at d 0 and boosted at d 28 and 56. Among them, the antibody injections were performed separately on the group that immunized with OVA plus FliC. Serum and saliva were collected at d 70. The experimental procedures are illustrated in Fig. 6C , upper. As shown in Fig. 6C , lower, FliC significantly enhanced an OVA-specific serum IgA and salivary IgA response rather than OVA alone. GM-CSF neutralizing antibody but not isotype control antibody impaired both FliC-and OVA-specific IgA production. These data were consistent with the results observed with the in vitro system, confirming that GM-CSF has a potential effect on TLR5-mediated airway DC modulation and subsequent IgA enhancement.
DISCUSSION
Now, the i.n. route is a well-accepted and efficient vaccination strategy, which has been widely used to great advantage in local mucosal immune responses. However, there is no unified method for nasal instillation. Inhaled liquid volumes vary from 10 to 50 ml [9, 20, 37] . Along with other researchers [19] , we have shown that regardless of the volume of inhaled liquid, i.n. immunization with flagellin may effectively enhance the final mucosal immune response [7, 9] . In the present study, we found that different inhaled volumes cause different initial activation in the airway tract (Supplemental Fig. 2) . When mice were i.n. immunized with flagellin in 10 ml liquid vol, only DCs in the upper-airway tract were activated. When the inhaled liquid volume was increased to 30 ml, flagellin flowed into the lung, resulting in DC activation in both the upperairway tract and the lung [20] (Supplemental Fig. 2 ). With the consideration that the lung is relatively sterile and a susceptible organ compared with the upper-airway tract, activation of the TLR pathway in the lung is risky and may cause pulmonary inflammation [38] . Thus, we recommend that the adjuvant dosage, as well as the liquid volume, for i.n immunization is limited to avoid direct inhalation of adjuvant and/or antigen into the lung. A moderate activation solely in the upper-airway tract would be a better choice, especially when microbe-based i.n. adjuvants are used.
When flagellin is delivered into the nasal cavity, NECs are the first sentinel cells in contact. Flagellin then passes across the NEC barrier to reach the nasal mucus layer (Supplemental Fig. 3 ), where its uptake by nasal-resident APCs occurs. Previous research has shown that TLR5 expression in airway DCs is much lower than in AECs, suggesting that airway DCs are not the target cells of flagellin [20] . Our present results showed that airway DCs may respond slightly to direct stimulation from flagellin in a TLR5-dependent manner, demonstrated as a slight up-regulation of CD80 on DCs ( Fig. 2A and E) . However, this type of direct stimulation was insufficient to support a subsequent DC-mediated IgA response (Fig. 2C) . Based on our present results (Figs. 1 and 2 and Supplemental Fig. 2) , we suggest that airway DCs receive 2 activation signals: one from flagellin and the other from flagellin-activated NECs; the initial TLR5 activation of NECs is an essential step for the functional activation of airway DCs. This helps explain, at least partly, why mucosal immune responses are induced by a mucosal immunization route but not by a systemic one. Whether these observations are specific to nasal immunization with flagellin or can be extended to other mucosal adjuvants warrants further investigation.
Gradual attention has been drawn to the modulation of mucosal epithelial cells and its orchestration of mucosal immunity [39] . TLR signaling in IECs has been studied intensively for its profoundly beneficial role in maintaining host bacterial symbiosis and contributes considerably to IgA synthesis in the gut [40] . In contrast, TLR signaling in the airway epithelium is less studied. Recent studies have investigated AECs, and TLR signaling of AECs plays an important role in airway mucosal immunity [22, 41, 42] . Our data on TLR5 expression and signaling showed some differences between AECs and IECs. The location of TLR5 in AECs (Supplemental Fig. 4) is mainly on the apical surface, which is the opposite of the basolateral expression on IECs [43] . This suggests that TLR5 modulates mucosal immunity differently in the airway and gastrointestinal tract.
Our study further identified epithelial factors involved in the adjuvant effect of flagellin. We showed that neutralization of GM-CSF, but not IL-6 or TSLP, in vitro in the conditioned medium inhibited the up-regulation of CD80 and CD86 on DCs significantly, as well as DC-mediated IgA induction. Moreover, the blocking of GM-CSF in vivo decreased the activation of nasal DCs and CLN DCs and also impaired the FliC-enhanced IgA response in mice. Therefore, we suggest that GM-CSF secreted by TLR5-activated NECs significantly contributes to the functional modulation of airway DCs and subsequent IgA response.
As a well-known hematopoietic growth factor that controls the development and differentiation of the myeloid lineage [44] , GM-CSF has also long been used for the in vitro generation of DCs from monocytes and bone marrow cells. Intensive studies have reported on the versatile roles of GM-CSF [45, 46] , but its function in modulating mucosal DCs and mediating subsequent mucosal immunity are not yet known. GM-CSF binds specifically to its receptor, composed of a GMRa and a b-chain shared with IL-3 and IL-5 [47] . Myeloid lineage cells, including DCs, macrophages, monocytes, neutrophils, eosinophils, and basophils, usually express GMRa, but T cells, NK cells, and B cells do not. Therefore, GM-CSF does not act on lymphoid cells directly [48] . In our experiment system, conditioned medium from FliC-stimulated WT mNECs containing GM-CSF performed its IgA enhancement function through modulation of airway DCs but had no direct effect on naive B cells (data not shown).
According to our data, when flagellin is used as an i.n. adjuvant, the scenario can be described briefly as follows (Fig. 7) : NECs express a very low level of GM-CSF in the normal state, but this is up-regulated sharply upon TLR5 stimulation (Fig. 4) . The up-expressed and released GM-CSF from NECs modulates nasal DCs to an activated, functional state. The modulated DCs somehow enhance IgA production by promotion of IgA classswitch via T cell-dependent or/and T cell-independent pathways [12] . It should be noted that some soluble factors have been reported to be important in T cell-independent IgA classswitching, such as BAFF, APRIL, IL-6, RA, and TGF-b [12, 49] . In our experiments, DCs released higher amounts of IL-6 in response to LPS after being educated by the conditioned medium of FliC-activated mNECs when compared with nonconditioned DCs (data not shown), and this may drive the de novo generation of IgA-secreting cells (Fig. 3D) . A recent study showed that GM-CSF, produced by a stromal cell population in the intestinal lamina propria, is required for RA-induced retinaldehyde dehydrogenase type 2 expression in DCs [50] . We speculate that GM-CSF, derived from TLR5-activated NECs, may modulate nasal DCs, promoting DCs to secrete IL-6 and/or RA to enhance IgA class-switching. The understanding of how these modulated DCs develop an IgA response will be a major topic for future research.
In conclusion, the present study confirmed that NECs play an important role in TLR5-mediated DC activation and IgA enhancement. Flagellin-activated NECs secreted certain cytokines, particularly GM-CSF, and these conveyed the TLR5 signal of NECs to mucosal DCs, resulting in the subsequent IgA responses. The current data help us to understand TLR5-mediated immune activation in the airway and provide insight into a new function of epithelial GM-CSF in modulating immune responses. 
